0

Age-Related Macular Degeneration (AMD) Therapeutics Market by Type and Geography - Forecast and Analysis 2022-2026

  • Published: Oct 2021
  • Pages: 120
  • SKU: IRTNTR70644
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The age-related macular degeneration market share is expected to increase by USD 9.37 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 12.6%.

This age-related macular degeneration (AMD) therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers age-related macular degeneration (AMD) therapeutics market segmentation by type (wet AMD and dry AMD) and geography (North America, Europe, Asia, and Rest of World (ROW)). The age-related macular degeneration therapeutics market report also offers information on several market vendors, including Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., Allegro Ophthalmics LLC, Amgen Inc., Apellis Pharmaceuticals Inc., Bausch Health Co Inc, Bayer AG, F. Hoffmann La Roche Ltd., Formycon AG, Intas Pharmaceuticals Ltd., Novartis AG, Outlook Therapeutics Inc., Regeneron Pharmaceuticals Inc., Reliance Industries Ltd., Santen Pharmaceutical Co. Ltd., and Xbrane Biopharma AB among others.

What will the Age-related Macular Degeneration Market Size be During the Forecast Period?

Age-related Macular Degeneration Market Size

Download Report Sample to Unlock the Age-related Macular Degeneration Market Size for the Forecast Period and Other Important Statistics

 

Age-related Macular Degeneration Market: Key Drivers, Trends, and Challenges

The high prevalence of AMD is notably driving the age-related macular degeneration (AMD) therapeutics market growth, although factors such as the lack of approved therapies for dry AMD may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the age-related macular degeneration (AMD) therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Age-related Macular Degeneration Market Driver

One of the key factors driving growth in the AMD therapeutics market is the high prevalence of AMD. Globally, the prevalence of AMD is very high, owing to the presence of high-risk factors for developing the condition. According to the CDC, AMD is the leading cause of blindness globally and is the leading cause of vision loss and blindness in people aged 65 years and above. Risk factors such as ageing, smoking, high cholesterol, and high blood pressure are the major contributors to the development of AMD. The prevalence rate of dry AMD is around 85%-90%, and wet AMD is 10%-15%. Despite the high prevalence of dry AMD, no approved therapies are available in the market for the treatment of the condition. Thus, the high prevalence, coupled with the huge unmet medical need for dry AMD, is expected to drive market growth during the forecast period.

Key Age-related Macular Degeneration Market Trend

Strategic alliances are an age-related macular degeneration therapeutics market trend that is expected to have a positive impact in the coming years. The lack of approved therapies for AMD has encouraged pharmaceutical companies to actively investigate new drugs for the treatment of the condition. While developing these new drugs, companies are forming collaborations with other companies, which will speed up the development process and raise investments in research activities. For instance, In October 2020, Gemini Therapeutics, a clinical-stage precision medicine company that develops innovative treatments for genetically defined AMD, and FS Development Corp., a special-purpose acquisition company (sponsored by Foresite Capital), entered into a merger agreement. This agreement will help in the development of advanced treatments or therapeutics for AMD. Such factors are expected to drive market growth during the forecast period.

Key Age-related Macular Degeneration Market Challenge

The lack of approved therapies for dry AMD will be a major challenge for the age-related macular degeneration therapeutics market during the forecast period. Despite the high prevalence, dry AMD remains untreated due to a historically poor understanding of the disease. Currently, all the available treatments for AMD are only for wet AMD, and there are no approved drugs for the treatment of dry AMD. Off-label drugs are largely used for the symptomatic treatment of dry AMD. Vitamin C, vitamin E, lutein, and copper supplements help in reducing the risk of vision loss in dry AMD. Currently, two drugs are in the Phase III clinical stage of development for the treatment of dry AMD. Hence, the lack of approved therapies and the presence of only a few late-stage molecules for the treatment of dry AMD is expected to restrain the market growth.

This age-related macular degeneration market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global age-related macular degeneration (AMD) therapeutics market as a part of the pharmaceutical market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the AMD therapeutics market during the forecast period.

Who are the Major Age-related Macular Degeneration Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • Alimera Sciences Inc.
  • Alkeus Pharmaceuticals Inc.
  • Allegro Ophthalmics LLC
  • Amgen Inc.
  • Apellis Pharmaceuticals Inc.
  • Bausch Health Co Inc
  • Bayer AG
  • F. Hoffmann La Roche Ltd.
  • Formycon AG
  • Intas Pharmaceuticals Ltd.
  • Novartis AG
  • Outlook Therapeutics Inc.
  • Regeneron Pharmaceuticals Inc.
  • Reliance Industries Ltd.
  • Santen Pharmaceutical Co. Ltd.
  • Xbrane Biopharma AB

 

This statistical study of the AMD therapeutics market encompasses successful business strategies deployed by the key vendors. The AMD therapeutics market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

  • Alkeus Pharmaceuticals Inc. - The company offers age-related macular degeneration therapeutics products under the brand name Alk-001.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The age-related macular degeneration market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Age-related Macular Degeneration Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the age-related macular degeneration market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Age-related Macular Degeneration Market?

Age-related Macular Degeneration Market Share by Geography

For more insights on the market share of various regions Request PDF Sample now!

42% of the market’s growth will originate from North America during the forecast period. US and Canada are the key markets for age-related macular degeneration (AMD) therapeutics in North America. Market growth in this region will be faster than the growth of the market in the European regions.

The high prevalence of AMD will facilitate the age-related macular degeneration (AMD) therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The outbreak of COVID-19 had a negative impact on the AMD therapeutics market in North America in 2020. Owing to the harmful effects of COVID-19, a considerable number of AMD treatment facilities were forced to lay off employees in 2020. As a result, AMD treatment facilities had to face personnel shortages and stockpiles, which, in turn, led to disruptions in the supply chain of production of AMD therapeutics. However, several vendors across the market adopted strategies to promote their offerings online in the second half of 2020, allowing the regional market to respond to the pandemic negative impacts by registering growth through online channels. 

What are the Revenue-generating Type Segments in the Age-related Macular Degeneration Market?

Age-related Macular Degeneration Market Share

To gain further insights on the market contribution of various segments Request PDF Sample

The age-related macular degeneration (AMD) therapeutics market share growth by the wet AMD segment will be significant during the forecast period. The growth of this segment is primarily driven by the increasing use of vascular endothelial growth factor (VEGF) inhibitors, which are largely used for the treatment of wet AMD. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the age-related macular degeneration market size and actionable market insights on post COVID-19 impact on each segment.

 

Age-related Macular Degeneration Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 12.6%

Market growth 2022-2026

$ 9.37 billion

Market structure

Fragmented

YoY growth (%)

12.0

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 42%

Key consumer countries

US, Germany, UK, France, and Japan

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., Allegro Ophthalmics LLC, Amgen Inc., Apellis Pharmaceuticals Inc., Bausch Health Co Inc, Bayer AG, F. Hoffmann La Roche Ltd., Formycon AG, Intas Pharmaceuticals Ltd., Novartis AG, Outlook Therapeutics Inc., Regeneron Pharmaceuticals Inc., Reliance Industries Ltd., Santen Pharmaceutical Co. Ltd., and Xbrane Biopharma AB

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID- 19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Age-related Macular Degeneration Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive age-related macular degeneration market growth during the next five years
  • Precise estimation of the age-related macular degeneration market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behaviour
  • The growth of the age-related macular degeneration industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of age-related macular degeneration market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Type

    • 5.1 Market segments
      • Exhibit 24: Chart on Type - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
    • 5.2 Comparison by Type
      • Exhibit 26: Chart on Comparison by Type
      • Exhibit 27: Data Table on Comparison by Type
    • 5.3 Wet AMD - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Wet AMD - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on Wet AMD - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on Wet AMD - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Wet AMD - Year-over-year growth 2021-2026 (%)
    • 5.4 Dry AMD - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Dry AMD - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Dry AMD - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Dry AMD - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Dry AMD - Year-over-year growth 2021-2026 (%)
    • 5.5 Market opportunity by Type
      • Exhibit 36: Market opportunity by Type ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 40: Chart on Geographic comparison
      • Exhibit 41: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Germany - Market size and forecast 2021-2026
      • Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.9 UK - Market size and forecast 2021-2026
      • Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.10 China - Market size and forecast 2021-2026
      • Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
    • 7.11 Canada - Market size and forecast 2021-2026
      • Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
    • 7.12 Market opportunity by geography
      • Exhibit 78: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 81: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 82: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 83: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 84: Matrix on vendor position and classification
            • 10.3 Alkeus Pharmaceuticals Inc.
              • Exhibit 85: Alkeus Pharmaceuticals Inc. - Overview
              • Exhibit 86: Alkeus Pharmaceuticals Inc. - Product / Service
              • Exhibit 87: Alkeus Pharmaceuticals Inc. - Key offerings
            • 10.4 Allegro Ophthalmics LLC
              • Exhibit 88: Allegro Ophthalmics LLC - Overview
              • Exhibit 89: Allegro Ophthalmics LLC - Product / Service
              • Exhibit 90: Allegro Ophthalmics LLC - Key offerings
            • 10.5 Amgen Inc.
              • Exhibit 91: Amgen Inc. - Overview
              • Exhibit 92: Amgen Inc. - Product / Service
              • Exhibit 93: Amgen Inc. - Key offerings
            • 10.6 Apellis Pharmaceuticals Inc.
              • Exhibit 94: Apellis Pharmaceuticals Inc. - Overview
              • Exhibit 95: Apellis Pharmaceuticals Inc. - Product / Service
              • Exhibit 96: Apellis Pharmaceuticals Inc. - Key offerings
            • 10.7 Bayer AG
              • Exhibit 97: Bayer AG - Overview
              • Exhibit 98: Bayer AG - Business segments
              • Exhibit 99: Bayer AG - Key offerings
              • Exhibit 100: Bayer AG - Segment focus
            • 10.8 F. Hoffmann La Roche Ltd.
              • Exhibit 101: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 102: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 103: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 104: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 105: F. Hoffmann La Roche Ltd. - Segment focus
            • 10.9 Formycon AG
              • Exhibit 106: Formycon AG - Overview
              • Exhibit 107: Formycon AG - Key offerings
            • 10.10 Novartis AG
              • Exhibit 108: Novartis AG - Overview
              • Exhibit 109: Novartis AG - Business segments
              • Exhibit 110: Novartis AG - Key offerings
              • Exhibit 111: Novartis AG - Segment focus
            • 10.11 Outlook Therapeutics Inc.
              • Exhibit 112: Outlook Therapeutics Inc. - Overview
              • Exhibit 113: Outlook Therapeutics Inc. - Product / Service
              • Exhibit 114: Outlook Therapeutics Inc. - Key offerings
            • 10.12 Reliance Industries Ltd.
              • Exhibit 115: Reliance Industries Ltd. - Overview
              • Exhibit 116: Reliance Industries Ltd. - Business segments
              • Exhibit 117: Reliance Industries Ltd. - Key offerings
              • Exhibit 118: Reliance Industries Ltd. - Segment focus

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 119: Inclusions checklist
                • Exhibit 120: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 121: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 122: Research methodology
                • Exhibit 123: Validation techniques employed for market sizing
                • Exhibit 124: Information sources
              • 11.5 List of abbreviations
                • Exhibit 125: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Age-related Macular Degeneration market growth will increase by $4003.90 million during 2020-2025.
              The age-related macular degeneration market is expected to grow at a CAGR of 5.93% during 2020-2025.
              Technavio has segmented the age-related macular degeneration market by type (Wet AMD and Dry AMD) and geographic (North America, Europe, Asia, and ROW).
              AbbVie Inc., Alkeus Pharmaceuticals Inc., Amgen Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Lupin Ltd., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc. are a few of the key vendors in the age-related macular degeneration market.
              North America will register the highest growth rate of 43.72% among the other regions. Therefore, the age-related macular degeneration market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the age-related macular degeneration market growth are:
              • High prevalence of AMD
              The age-related macular degeneration market vendors should focus on grabbing business opportunities from the wet amd segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>